Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder

Keyphrases

• Antipsychotics 16%
• Brief Psychiatric Rating Scale 33%
• Cannabinoid Receptor 1 (CB1R) 16%
• CB1 Antagonist 16%
• Change from Baseline 16%
• Clinical Global Impression 33%
• Control Evaluation 100%
• Endpoint Analysis 16%
• Evidence-based 16%
• Fixed-dose Combination 16%
• Haloperidol 50%
• Investigational Drugs 33%
• Negative Syndrome 50%
• Neurokinin B 16%
• Neurotensin 16%
• NK3 Antagonist 33%
• Non-dopaminergic 16%
• Novel Design 16%
• NTS1 33%
• Number of Patients 16%
• Placebo 100%
• Placebo-controlled 100%
• Plasma Parameters 16%
• Psychopathology 16%
• Psychosis 33%
• Schizoaffective Disorder 100%
• Schizophrenia Symptoms 100%
• Schizophrenia Treatment 100%
• Serotonin 2A 16%
• Serotonin 2A Receptor (5-HT2AR) 66%
• Severity of Illness Score 33%
• SR141716 16%
• SR142801 16%
• SR48692 16%

Pharmacology, Toxicology and Pharmaceutical Science

• 4 (para chlorophenyl) 1 [3 (para fluorobenzoyl)propyl] 4 piperidinol 42%
• Antipsychotic 14%
• Cannabinoid 14%
• Diseases 28%
• Eplivanserin 14%
• Investigational Drug 28%
• Meclinertant 14%
• Negative Syndrome 42%
• Neurokinin 14%
• Neurokinin 3 Receptor Antagonist 28%
• Neurotensin 14%
• Osanetant 14%
• Placebo 100%
• Positive Syndrome 42%
• Rimonabant 14%
• Schizoaffective Psychosis 100%
• Serotonin 14%

Neuroscience

• Antipsychotic 14%
• Blood Plasma 14%
• Cannabinoid 14%
• Haloperidol 42%
• Negative Syndrome 42%
• Neurokinin 14%
• Neurotensin 14%
• Placebo 100%
• Positive Syndrome 42%
• Rimonabant 14%
• Schizoaffective Disorder 100%
• Serotonin 14%
• Treatment of Schizophrenia 100%